Lessons from the Fourth Metronomic and Anti-angiogenic Therapy
Meeting, 24-25 June 2014, Milan

J 2014

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan

BOUCHE, Gauthier, Nicolas ANDRÉ, Shripad BANAVALI, Frank BERTHOLD, Alfredo BERRUTI et. al.

Základní údaje

Originální název

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan

Autoři

BOUCHE, Gauthier (56 Belgie), Nicolas ANDRÉ (250 Francie), Shripad BANAVALI (356 Indie), Frank BERTHOLD (276 Německo), Alfredo BERRUTI (380 Itálie), Guido BOCCI (380 Itálie), Giovanni BRANDI (380 Itálie), Ugo CAVALLARO (380 Itálie), Saviero CINIERI (380 Itálie), Marco COLLEONI (380 Itálie), Giuseppe CURIGLIANO (380 Itálie), Teresa Di DESIDERO (380 Itálie), Alexandru ENIU (642 Rumunsko), Nicola FAZIO (380 Itálie), Robert KERBEL (124 Kanada), Lisa HUTCHINSON (826 Velká Británie a Severní Irsko), Urszula LEDZEWICZ (840 Spojené státy), Elisabetta MUNZONE (380 Itálie), Eddy PASQUIER (250 Francie), Graciela O. SCHAROVSKY (32 Argentina), Yuval SHAKED (376 Izrael), Jaroslav ŠTĚRBA (203 Česká republika, garant, domácí), Martin VILLALBA (250 Francie) a Francesco BERTOLINI (380 Itálie)

Vydání

Ecancermedicalscience, Briston, Cancer Intelligence, 2014, 1754-6605

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/14:00076839

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3332/ecancer.2014.463

UT WoS

000215844400088

Klíčová slova anglicky

Adult; Anti-angiogenesis; Cancer; Child; Drug repurposing; Metronomic chemotherapy; Pharmacoeconomics

Štítky

EL OK

Příznaky

Recenzováno

Změněno: 14. 10. 2014 17:36, Soňa Böhmová

Anotace

V originále

The Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24-25 June 2014. The meeting was a true translational meeting where researchers and clinicians shared their results, experiences, and insights in order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, and optimal dosage are still not well understood and that the field would learn a lot from ancillary studies performed during the clinical trials of metronomic chemotherapies. From the pre-clinical side, new research findings indicate additional possible mechanisms of actions of metronomic schedule on the immune and blood vessel compartments of the tumour micro-environment. New clinical results of metronomic chemotherapy were presented in particular in paediatric cancers [especially neuroblastoma and central nervous system (CNS) tumours], in angiosarcoma (together with beta-blockers), in hepatocellular carcinoma, in prostate cancer, and in breast cancer. The use of repurposed drugs such as metformin, celecoxib, or valproic acid in the metronomic regimen was reported and highlighted the potential of other candidate drugs to be repurposed. The clinical experiences from low- and middle-income countries with affordable regimens gave very encouraging results which will allow more patients to be effectively treated in economies where new drugs are not accessible. Looking at the impact of metronomic approaches that have been shown to be effective, it was admitted that those approaches were rarely used in clinical practice, in part because of the absence of commercial interest for companies. However, performing well-designed clinical trials of metronomic and repurposing approaches demonstrating substantial improvement, especially in populations with the greatest unmet needs, may be an easier solution than addressing the financial issue. Metronomics should always be seen as a chance to come up with new innovative affordable approaches and not as a cheap rescue strategy.

Citovat

BOUCHE, Gauthier, Nicolas ANDRÉ, Shripad BANAVALI, Frank BERTHOLD, Alfredo BERRUTI, Guido BOCCI, Giovanni BRANDI, Ugo CAVALLARO, Saviero CINIERI, Marco COLLEONI, Giuseppe CURIGLIANO, Teresa Di DESIDERO, Alexandru ENIU, Nicola FAZIO, Robert KERBEL, Lisa HUTCHINSON, Urszula LEDZEWICZ, Elisabetta MUNZONE, Eddy PASQUIER, Graciela O. SCHAROVSKY, Yuval SHAKED, Jaroslav ŠTĚRBA, Martin VILLALBA a Francesco BERTOLINI. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience. Briston: Cancer Intelligence, 2014, roč. 8, č. 463, s. 1-18. ISSN 1754-6605. Dostupné z: https://dx.doi.org/10.3332/ecancer.2014.463.

@article{1202690,
   author = {Bouche, Gauthier and André, Nicolas and Banavali, Shripad and Berthold, Frank and Berruti, Alfredo and Bocci, Guido and Brandi, Giovanni and Cavallaro, Ugo and Cinieri, Saviero and Colleoni, Marco and Curigliano, Giuseppe and Desidero, Teresa Di and Eniu, Alexandru and Fazio, Nicola and Kerbel, Robert and Hutchinson, Lisa and Ledzewicz, Urszula and Munzone, Elisabetta and Pasquier, Eddy and Scharovsky, Graciela O. and Shaked, Yuval and Štěrba, Jaroslav and Villalba, Martin and Bertolini, Francesco},
   article_location = {Briston},
   article_number = {463},
   doi = {http://dx.doi.org/10.3332/ecancer.2014.463},
   keywords = {Adult; Anti-angiogenesis; Cancer; Child; Drug repurposing; Metronomic chemotherapy; Pharmacoeconomics},
   language = {eng},
   issn = {1754-6605},
   journal = {Ecancermedicalscience},
   title = {Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan},
   volume = {8},
   year = {2014}
}

TY  - JOUR
ID  - 1202690
AU  - Bouche, Gauthier - André, Nicolas - Banavali, Shripad - Berthold, Frank - Berruti, Alfredo - Bocci, Guido - Brandi, Giovanni - Cavallaro, Ugo - Cinieri, Saviero - Colleoni, Marco - Curigliano, Giuseppe - Desidero, Teresa Di - Eniu, Alexandru - Fazio, Nicola - Kerbel, Robert - Hutchinson, Lisa - Ledzewicz, Urszula - Munzone, Elisabetta - Pasquier, Eddy - Scharovsky, Graciela O. - Shaked, Yuval - Štěrba, Jaroslav - Villalba, Martin - Bertolini, Francesco
PY  - 2014
TI  - Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan
JF  - Ecancermedicalscience
VL  - 8
IS  - 463
SP  - 1-18
EP  - 1-18
PB  - Cancer Intelligence
SN  - 17546605
KW  - Adult
KW  - Anti-angiogenesis
KW  - Cancer
KW  - Child
KW  - Drug repurposing
KW  - Metronomic chemotherapy
KW  - Pharmacoeconomics
N2  - The Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24-25 June 2014. The meeting was a true translational meeting where researchers and clinicians shared their results, experiences, and insights in order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, and optimal dosage are still not well understood and that the field would learn a lot from ancillary studies performed during the clinical trials of metronomic chemotherapies. From the pre-clinical side, new research findings indicate additional possible mechanisms of actions of metronomic schedule on the immune and blood vessel compartments of the tumour micro-environment. New clinical results of metronomic chemotherapy were presented in particular in paediatric cancers [especially neuroblastoma and central nervous system (CNS) tumours], in angiosarcoma (together with beta-blockers), in hepatocellular carcinoma, in prostate cancer, and in breast cancer. The use of repurposed drugs such as metformin, celecoxib, or valproic acid in the metronomic regimen was reported and highlighted the potential of other candidate drugs to be repurposed. The clinical experiences from low- and middle-income countries with affordable regimens gave very encouraging results which will allow more patients to be effectively treated in economies where new drugs are not accessible. Looking at the impact of metronomic approaches that have been shown to be effective, it was admitted that those approaches were rarely used in clinical practice, in part because of the absence of commercial interest for companies. However, performing well-designed clinical trials of metronomic and repurposing approaches demonstrating substantial improvement, especially in populations with the greatest unmet needs, may be an easier solution than addressing the financial issue. Metronomics should always be seen as a chance to come up with new innovative affordable approaches and not as a cheap rescue strategy.
ER  -

BOUCHE, Gauthier, Nicolas ANDRÉ, Shripad BANAVALI, Frank BERTHOLD, Alfredo BERRUTI, Guido BOCCI, Giovanni BRANDI, Ugo CAVALLARO, Saviero CINIERI, Marco COLLEONI, Giuseppe CURIGLIANO, Teresa Di DESIDERO, Alexandru ENIU, Nicola FAZIO, Robert KERBEL, Lisa HUTCHINSON, Urszula LEDZEWICZ, Elisabetta MUNZONE, Eddy PASQUIER, Graciela O. SCHAROVSKY, Yuval SHAKED, Jaroslav ŠTĚRBA, Martin VILLALBA a Francesco BERTOLINI. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. \textit{Ecancermedicalscience}. Briston: Cancer Intelligence, 2014, roč.~8, č.~463, s.~1-18. ISSN~1754-6605. Dostupné z: https://dx.doi.org/10.3332/ecancer.2014.463.

Podrobný výpis o publikaci